We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 150

USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients

Post-Grant Proceedings as a Freedom-To-Operate Tool
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 30 2017

While some may take it as a given that patent owners view America Invents Act post-grant proceedingsinter partes reviews and post-grant

Janssen Biologic Tremfya Secures FDA Approval Following Use of Priority Review Voucher
  • Knobbe Martens
  • USA
  • July 25 2017

On July 13, 2017, the U.S. Food and Drug Administration approved Tremfya (guselkumab), a biologic manufactured by Janssen Biotech, for the treatment

House Takes Early Action on Noncontroversial Public Health Bills
  • Reed Smith LLP
  • USA
  • January 30 2017

Early in the new Congress, the House of Representatives has approved, without objection, the following bipartisan public health bills: H.R. 309, the

Addressing Zika’s Continued Threat to the Workplace
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • September 22 2016

The growing prevalence of the Zika virus in the United States has already presented a number of hurdles for employers striving to create a safe and

Biosimilar FDA Approvals on the Horizon As More States Enact Substitution Laws
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • August 30 2016

In a sign of growing scientific acceptance and understanding of the biosimilar regulatory pathway, FDA's Arthritis Advisory Committee (AAC) voted

Supporting Evidence, Not Counter-Punching, May Be Needed In An IPR
  • Marshall Gerstein & Borun LLP
  • USA
  • May 9 2016

In IPR2015-01537, Momenta petitioned for IPR of claims 1-15 of U.S. Patent No. 8,476,239 owned by Bristol-Myers Squibb (BMS) on grounds of

Long-chain fatty acids allegedly linked to autoimmune disease severity
  • Shook Hardy & Bacon LLP
  • USA
  • October 23 2015

An animal study has reportedly suggested that dietary long-chain fatty acids (LCFAs) can increase the severity of chronic-inflammatory diseases such

Orca Pharmaceuticals announces research collaboration with AstraZeneca to develop inhibitors to treat autoimmune diseases
  • Penningtons Manches LLP
  • United Kingdom
  • February 25 2015

Penningtons Manches' life sciences team has acted for Orca Pharmaceuticals, an Oxford-based biopharmaceutical company, on its three year

First Canadian decision on biologics: a new era begins
  • Fasken
  • Canada
  • February 10 2014

In AbbVie v. Janssen, the Federal Court of Canada recently handed down the first Canadian decision regarding a patent on biologic drugs. Before that